Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Managing recurrent Clostridium difficile infection (CDI) presents a significant challenge for clinicians and patients. Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent CDI, yet availability of a standardized, safe, and effective product has been lacking. Our aim in this study was to assess the safety and effectiveness of RBX2660 (microbiota suspension), a commercially prepared FMT drug manufactured using standardized processes and available in a ready-to-use format. METHODS: Patients with at least 2 recurrent CDI episodes or at least 2 severe episodes resulting in hospitalization were enrolled in a prospective, multicenter open-label study of RBX2660 administered via enema. Intensive surveillance for adverse events (AEs) was conducted daily for 7 days following treatment and then at 30 days, 60 days, 3 months, and 6 months. The primary objective was product-related AEs. A secondary objective was CDI-associated diarrhea resolution at 8 weeks. RESULTS: Of the 40 patients enrolled at 11 centers in the United States between 15 August 2013 and 16 December 2013, 34 received at least 1 dose of RBX2660 and 31 completed 6-month follow-up. Overall efficacy was 87.1% (16 with 1 dose and 11 with 2 doses). Of 188 reported AEs, diarrhea, flatulence, abdominal pain/cramping, and constipation were most common. The frequency and severity of AEs decreased over time. Twenty serious AEs were reported in 7 patients; none were related to RBX2660 or its administration. CONCLUSIONS: Among patients with recurrent or severe CDI, administration of RBX2660 via enema appears to be safe and effective. CLINICAL TRIALS REGISTRATION: NCT01925417.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the efficacy of retention enema had been once doubted, Orenstein and Dubberke et al. have proven it more efficient and safe than placebo in phase I and phase II recurrent CDI clinical trials.64,65”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [64]
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 2×
“Two randomized controlled trials of FMT predominantly recorded mild AEs similar to those found in our study [11, 27].”
BackgroundResultCohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641 · cited 1×
“Clostridium difficile infection (CDI) has become one of the most common healthcare-associated infections in the United States, affecting more than 500 000 people annually [1].”
BackgroundClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Gough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003 · cited 2×
“Minor and self-limited gastrointestinal symptoms similar to those seen in this study appear to be common [17].”
BackgroundResultKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904 · cited 1×
“Most studies that have assessed the impact of FMT are retrospective case series or systematic reviews of heterogeneously screened sources of microbiota with limited safety data [6, 7, 10].”
BackgroundBreaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724
Brandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672 · cited 1×
“Three systematic reviews and case series that included more than 5 patients and use of nonstandardized FMT products and procedures [3, 4, 7, 18] have concluded that AEs are infrequent.”
BackgroundKelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.133 · Cited by 636 · cited 1×
“One patient died during sedation for a colonoscopy [26].”
BackgroundSelf-citationYoungster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629 · cited 1×
“In a second study that used an encapsulated product, 30% of patients experienced cramps and bloating, which resolved within 3 days [13].”
Background
Cited by
Items 101–197 of 197
Villafuerte-Gálvez, J., & Kelly, C. P. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1344551 · Cited by 14
“It has published results of a Phase 2 trial [58]”
BackgroundEuropean Practice for CDI Treatment
Fitzpatrick, F., Skally, M., Brady, M., Burns, K., Rooney, C. M., & Wilcox, M. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72799-8_8 · Cited by 19
Nagarakanti, S., & Orenstein, R. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s400570 · Cited by 14
“1% (27/31) of patients had no further recurrences at week 8.(22) The Phase 2 open label clinical trial (PUNCH CD2) was conducted at 29 medical centers in the United States and Canada.”
BackgroundSelf-citationClostridioides difficile infection in inflammatory bowel disease: a clinical review
Tang, M., Wang, C., Xia, Y., Tang, J., Wang, J., & Shen, L. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2347955 · Cited by 15
Fecal Fixation: Fecal Microbiota Transplantation for Clostridium difficile Infection
Johnson, S., & Gerding, D. N. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw735 · Cited by 13
Faecal microbiota transplantation—A clinical view
Mattner, J., Schmidt, F., & Siegmund, B. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2016.02.003 · Cited by 12
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection
Bloom, P. P., & Young, V. B. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2154600 · Cited by 12
“This retention enema contains ≥10(7) live organisms/mL [72,73].”
BackgroundFeuerstadt, P., Allegretti, J. R., Dubberke, E. R., Guo, A. X., Harvey, A., Yang, M., García-Horton, V., Fillbrunn, M. K., Tillotson, G., Bancke, L. L., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00907-w · Cited by 15
Self-citationLive Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection
Pettit, N. N., Shaeer, K. M., & Chahine, E. B. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241239685 · Cited by 12
“, 16, 18-26 trials excluded pregnant people , those who intended to become pregnant during the study period , and those who were lactating or breastfeeding. vancomycin was the most commonly used anti-CDI anti-CDI agent at baseline screening periods for all these trials , the number of patients…”
Fighting against Clostridioides difficile infection: Current medications
Quan, M., Zhang, X., Fang, Q., Lv, X., Wang, X., & Zong, Z. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107198 · Cited by 13
Therapy for Clostridium difficile infection – any news beyond Metronidazole and Vancomycin?
Manthey, C. F., Eckmann, L., & Fuhrmann, V. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1362978 · Cited by 16
“no relapses of CDI for more than 8 weeks [78].”
BackgroundPrevention and treatment of recurrent Clostridioides difficile infection
Shin, J. H., & Warren, C. A. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000587 · Cited by 12
Shaffer, S. R., Witt, J. C., Targownik, L. E., Kao, D. H., Lee, C., Smieliauskas, F., Rubin, D. T., Singh, H., & Bernstein, C. N. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.09.025 · Cited by 12
Rakotonirina, A., Galpérine, T., & Allémann, É. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2095901 · Cited by 16
Chopra, T. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2171986 · Cited by 15
Fecal microbiota transplantation stimulates type 2 and tolerogenic immune responses in a mouse model
Moreau, G. B., Naz, F., & Petri, W. A. (2024) · Anaerobe · doi:10.1016/j.anaerobe.2024.102841 · Cited by 12
Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back
Miller, C. B., Bader, G. A., & Kay, C. (2026) · Current Gastroenterology Reports · doi:10.1007/s11894-025-01030-1 · Cited by 11
“An initial open-label study of RBX2660, a standardized microbiota suspension prepared from donor stool and delivered via enema bag, prompted a subsequent phase 2B randomized trial that demonstrated a single 150mL dose of the product to be superior to placebo for prevention of RCDI [ 19, 20].”
Goldenberg, S. D. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.12.004 · Cited by 11
Clostridioides difficile therapeutics: guidelines and beyond
Orenstein, R., & Patron, R. L. (2019) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936119868548 · Cited by 11
Self-citationGut microbiota and microbiota-based therapies for Clostridioides difficile infection
Chopra, T., Hecht, G. A., & Tillotson, G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1093329 · Cited by 13
Eaton, E., Tamhane, A. R., Burkholder, G., Willig, J. H., Saag, M. S., & Mugavero, M. J. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw109 · Cited by 10
“chronic conditions such as insomnia, pain, infections, and bowel disease; understanding extrinsic influences on drug durability has broad implications [6–9].”
BackgroundAlonso, C. D., Tillotson, G., Bidell, M. R., Guthmueller, B., Hoeyer, F., Fischer, M., & Dubberke, E. R. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf117 · Cited by 14
“Outcomes in study participants who were IC and received RBL [14, 18–20] or other FDA-approved microbiota-based live biotherapeutics [21, 22] have not been reported and are of clinical interest.”
Self-citationClaypool, J., Lindved, G., Myers, P. N., Ward, T., Nielsen, H. B., & Blount, K. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2520412 · Cited by 12
“24 In a randomized, placebo-controlled, phase 3 study (PUNCH TM CD3; NCT03244644), RBL was superior to placebo in preventing rCDI, 16 and restorative shifts in participants’ gut microbiome and metabolome compositions were detected as early as 1 week after RBL administration and sustained for ≥6…”
Ma, J., & Dubberke, E. R. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4377 · Cited by 12
Self-citationRecent developments in the management of recurrent Clostridioides difficile infection
Mendo-López, R., Villafuerte-Gálvez, J., White, N., Mahoney, M. V. G., Kelly, C. P., & Alonso, C. D. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102108 · Cited by 11
A Review of Therapies for Clostridioides difficile Infection
Morado, F., & Nanda, N. (2024) · Antibiotics · doi:10.3390/antibiotics14010017 · Cited by 10
“Of the 188 reported AEs, the most cited were mild to moderate in severity, primarily GI, and all self-limited: diarrhea 24%, flatulence 14%, abdominal pain and cramping 13%, and constipation 13% [65].”
Tillotson, G., Archbald‐Pannone, L. R., Johnson, S., Ng, S., Ando, M., Harvey, A., Bancke, L. L., & Feuerstadt, P. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac703 · Cited by 11
What’s New and What’s Next in Fecal Microbiota Transplantation?
Baydoun, H., Hussain, N., Wu, K., Kelly, C. R., & Fischer, M. (2025) · Biologics · doi:10.2147/btt.s486372 · Cited by 17
Therapeutics for Clostridioides difficile infection: molecules and microbes
Khanna, S., & Voth, E. R. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2250716 · Cited by 8
Blair, H. A. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-01023-y · Cited by 10
“Prevention of recurrent CDI with RBX2660 was associated with restoration of the intestinal microbiome, with responders’ microbiomes showing greater microbiome diversity and becoming more similar to RBX2660 [10, 11].”
BackgroundLin, Z., Iqbal, Z., Ortíz, J. F., Khan, S. A., & Jahan, N. (2020) · Cureus · doi:10.7759/cureus.9653 · Cited by 8
Keen, E. C., Tasoff, P., Hink, T., Reske, K. A., Burnham, C. D., Dantas, G. A., Kwon, J. H., & Dubberke, E. R. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa042 · Cited by 7
Self-citationBoyle, B. L., & Khanna, S. (2024) · Future Microbiology · doi:10.1080/17460913.2024.2364583 · Cited by 9
Duo, H., Yang, Y., Zhang, G., Chen, Y., Cao, Y., Luo, L., Pan, H., & Ye, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1430724 · Cited by 7
Encapsulation protocol for fecal microbiota transplantation
Sipos, D., Varga, A., Kappéter, Á., Halda-Kiss, B., Kása, P., Pál, S., Kocsis, B., & Péterfi, Z. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1424376 · Cited by 8
“The product can be stored at room temperature for up to 2 days prior to administration (Orenstein et al., 2016).”
BackgroundPeritore‐Galve, F. C., Kroh, H. K., Shupe, J. A., Ehni, A. G., Rodríguez, R. C., Kordus, S. L., Washington, M. K., Knippel, R. J., Stanley, A. M., Gamson, A., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013651 · Cited by 9
“Prevention and treatment of primary and recurrent CDI remains a significant clinical challenge despite recent advancements in antibiotic therapies and live microbial therapeutics [1,14,15,29].”
Khanna, S., Yoho, D. S., Handel, D. V., Clark, B. J., Awad, T., Guthmueller, B., Armandi, D., Knapple, W., Safdar, N., Baggott, B. B., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251339697 · Cited by 12
Clostridium difficile infection: Updates in management
Tariq, R., & Khanna, S. (2016) · Indian Journal of Gastroenterology · doi:10.1007/s12664-016-0719-z · Cited by 8
McFarland, L. V., Goldstein, E. J. C., & Kullar, R. (2023) · Microorganisms · doi:10.3390/microorganisms11061534 · Cited by 7
“The safety and efficacy of RBX2660 have been tested in two phase 2 studies [100,101], and in a phase 3 efficacy trial (PUNCH CD3) [85].”
BackgroundMehta, N., Goodenough, D., Gupta, N., Thomas, S., Mehta, C. C., Prakash, R., Woodworth, M. H., Kraft, C. S., & Fridkin, S. K. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae309 · Cited by 5
Human microbiome: Impact of newly approved treatments on C. difficile infection
Bland, C. M., Love, B. L., & Jones, B. M. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae249 · Cited by 7
Fecal Microbiota, Live-jslm (RBL; REBYOTA™) for Recurrent Clostridioides difficile Infection
Garcia, M. L., Castex, J., Duhaime, E., & Monk, M. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105195 · Cited by 5
Berry, P., & Khanna, S. (2024) · Future Microbiology · doi:10.1080/17460913.2024.2403892 · Cited by 6
Gonzales-Luna, A. J., & Carlson, T. J. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-00729-8 · Cited by 5
Reveles, K. R., Gonzales-Luna, A. J., Golan, Y., Alonso, C. D., Guthmueller, B., Tan, X., Bidell, M. R., Pokhilko, V., Crawford, C. V., & Skinner, A. M. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae341 · Cited by 6
“They also undergo rigorous screening procedures and pathogen testing to maximize patient safety [1, 17].”
BackgroundDeterding, K., Spinner, C. D., Schott, E., Welzel, T. M., Gerken, G., Klinker, H., Spengler, U., Wiegand, J., Wiesch, J. S. Z., Pathil, A., et al. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616678364 · Cited by 6
Self-citationKumari, M., & Kokkiligadda, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822909-5.00004-6 · Cited by 6
Transitions of care in Clostridioides difficile infection: a need of the hour
Khanna, S., Lett, J. E., Lattimer, C., & Tillotson, G. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221078684 · Cited by 11
Fecal Microbiota Transplantation
Borody, T. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54843-4.00018-0 · Cited by 7
Tran, M.-C. N., Kullar, R., & Goldstein, E. J. C. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1581763 · Cited by 5
Emerging alternatives against Clostridioides difficile infection
Romero-Rodríguez, A., de la Peña, C. M., Troncoso-Cotal, S., Guzmán, C., & Sánchez, S. (2022) · Anaerobe · doi:10.1016/j.anaerobe.2022.102638 · Cited by 5
Oneto, C., & Khanna, S. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002577 · Cited by 5
European Practice for CDI Treatment
Fitzpatrick, F., Brennan, R., van Prehn, J., Skally, M., Brady, M., Burns, K., Rooney, C. M., & Wilcox, M. H. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-42108-2_4 · Cited by 8
Vinterberg, J. E., Oddsdottir, J., Nye, M., & Pinton, P. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01105-y · Cited by 7
Exploring ways to improve CDI outcomes
Galpérine, T., & Guery, B. P. (2018) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2017.10.009 · Cited by 4
Rise to the Challenge: Master the Management of Clostridioides difficile Infection
Voth, E. R., & Khanna, S. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.02.022 · Cited by 5
Cotter, J. M., Nicholson, M. R., & Kociolek, L. K. (2019) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piz062 · Cited by 6
Khanna, S., Yoho, D. S., Handel, D. V., Clark, B. J., Awad, T., Guthmueller, B., Armandi, D., Knapple, W., Safdar, N., Baggott, B. B., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251396744 · Cited by 5
Knapple, W., Yoho, D. S., Sheh, A., Thul, J., & Feuerstadt, P. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241239547 · Cited by 3
Advancements in the Pathogenesis, Diagnosis, and Therapeutic Implications of Intestinal Bacteria
Lu, D., Ma, X., Tao, K., & Lei, H. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47020106 · Cited by 3
“In recent years, the interactions in holobiont in disease processes have gained significant attention, with many studies demonstrating their potential not only in treating gastrointestinal diseases but also in addressing conditions affecting other systems by targeting the gut microbiome.”
Aroniadis, O. C., Guthmueller, B., Dehlin, K., Srivastava, S., Feuerstadt, P., Lembo, A. J., & Weber, H. C. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01208-0 · Cited by 3
Engineering live bacterial therapeutics to treat human diseases
Hwang, I. Y. (2023) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2023.100492 · Cited by 4
Future Microbiome Therapeutics for Clostridioides difficile Infection
Fischer, M., & Ray, A. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002576 · Cited by 3
Self-citationHunt, A., Drwiega, E. N., Wang, Y., & Danziger, L. H. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae066 · Cited by 3
Javed, Q. U. A., Afzal, M., Ilyas, K., Sarfraz, A., & Sarfraz, Z. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.12.020 · Cited by 4
Fecal Microbiota Transplant vs Oral Vancomycin Taper: Important Undiscussed Limitations
Jansen, J. W. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix093 · Cited by 3
Clostridioides (Clostridium) difficile infection: Review of literature
Trad, G., Sodhi, V., Brockway, M. D., Sheikhan, N., Gheriani, A. G., Astor, O., & Gemil, H. (2022) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2022.14.2.0366 · Cited by 2
“The overall response was 87.1% [38].”
InfluentialCotto, C., Baker, K. A., Fallon, E., & Rimon, S. (2024) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000847 · Cited by 2
“…PUNCH CD2, PUNCH Open-label) (Blount, Shannon, Deych, Jones, 2019; Dubberke et al., 2018; Dubberke, Orenstein, Khanna, Guthmueller, Lee, 2023; Langdon et al., 2021; Orenstein et al., 2016), and 2 Phase 3 trials (PUNCH CD3 and PUNCH CD3-OLS [NCT03931941; completed late 2023]) (Khanna et al., 2022).”
Exploring the human microbiome: Its role and impact on overall health and disease prevention
Alotaibi, F. M., Almazam, A. A., Alenezi, S. Z., Alanazi, M. H., Lamfon, N. A., Albalawi, A. E. A., Al-Nasser, N. S., & Altheyab, S. A. (2018) · International Journal of Health Sciences · doi:10.53730/ijhs.v2ns1.15085 · Cited by 1
New investigational agents for the treatment of Clostridioides difficile infections
Tran, M.-C. N., Eubank, T. A., Kullar, R., McFarland, L. V., Garey, K. W., & Goldstein, E. J. C. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2579016 · Cited by 1
“Rebyota (RBX2660) is a commercially prepared, standardized, fecal microbiota suspension that is packaged into a single dose, ready to use enema bag [56].”
Lee, C., Feuerstadt, P., Louie, T., Bancke, L. L., Guthmueller, B., Harvey, A., Hoeyer, F., Orenstein, R., Dubberke, E. R., & Khanna, S. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251395566 · Cited by 1
Self-citationFecal microbiota transplantation in chronic liver disease: Current and future state of the art
Bloom, P. P., & Khanna, S. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000927 · Cited by 1
“[76] REBYOTA is administered rectally, each dose contains ≥ 10 7 live organisms per milliliter(s) of suspension, and it is also FDA-approved to prevent rCDI.”
Chopra, T., Handel, D. V., Baggott, B. B., Orenstein, R., Reveles, K. R., Guthmueller, B., Srivastava, S., & Khanna, S. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01374-9 · Cited by 1
“Findings from the RBL clinical development program indicate consistent efficacy across multiple study designs, including randomized controlled studies, open-label studies, and real-world analyses [27–35].”
InfluentialSelf-citationTransplantation of encapsulated fecal microbiota: research progress and future trends
Lin, M.-L., & Gao, H. (2026) · World Journal of Pediatrics · doi:10.1007/s12519-026-01056-z · Cited by 1
Consultants, M. I. D., Hise, N. V., Tillotson, G., Meehan, J., Ghera, E., Harting, B. P., & Nathan, R. V. (2023) · Private Practice Infectious Disease · doi:10.55636/ppid3020001 · Cited by 1
Jiménez-González, C., Vallejo, I. G., Sordo, D., Medina, J. M., Alonso‐Peña, M., & Crespo, J. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00670-7 · Cited by 3
Clinical Translation of Microbe-Based Therapies
Murthy, S., Balagurunathan, R., Anbalmani, S., & Nagarajan, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-1777-4_11 · Cited by 1
Microbiota restoration for recurrent Clostridioides difficile infection
Khanna, S. (2024) · Panminerva Medica · doi:10.23736/s0031-0808.24.05111-5 · Cited by 2
Durable Prevention of Recurrent C. Difficile Infection with RBX2660: Results of the PUNCH CD 2 Trial
Ramesh, M. S., Khanna, S., Messer, J., & Adams, M. (2016) · The American Journal of Gastroenterology · doi:10.14309/00000434-201610001-00194 · Cited by 1
Self-citationMicrobiome Therapeutics: Emerging Concepts and Challenges
Sarada, J., Anju, S., Aparna, Y., & Anuradha, K. T. (2021) · Springer eBooks · doi:10.1007/978-981-16-3156-6_11 · Cited by 1
Clostridium Difficile Infections: Epidemiology, Diagnosis, and Treatment
McFarland, L. V., Surawicz, C. M., & Vindigni, S. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch19 · Cited by 1
Etifa, P. (2021) · University of Hertfordshire Research Archive (University of Hertfordshire) · doi:10.18745/th.23919 · Cited by 4
A Standardized Fecal Microbiota Preparation for Recurrent C. difficile Infection
Ampel, N. M. (2016) · Journal watch · doi:10.1056/nejm-jw.na40510
Clostridium difficile: Current Status and Treatment Perspectives
Suay‐García, B., & Pérez‐Gracia, M. T. (2016) · Journal of Infectious Diseases and Treatment · doi:10.21767/2472-1093.100006
Chung, S. H. (2017) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2017.70.5.269
Manipulating the gut microbiota
Renwick, S., & Allen‐Vercoe, E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820602-7.00010-6
The hardware method of biomaterial preparation for fecal transplantation
Shedoeva, L. R., Chashkova, E. Y., Геннадьевна, К. О., & Kogan, G. Y. (2020) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2020-48-060
Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections
Signorette, J. P., de Oliveira, R. T. D., Montiel, J. M., & Longo, P. L. (2021) · International Journal of Nutrology · doi:10.1055/s-0040-1718996
Control of Clostridium difficile Infection by Defined Microbial Communities
Collins, J., & Auchtung, J. M. (2018) · ASM Press eBooks · doi:10.1128/9781555819705.ch11 · Cited by 1
A Tour-d’Horizon of microbiota therapeutics for metabolic disorders
Saifi, S., Swaminathan, A., Devi, P., Chattopadhyay, P., Gupta, S., Garg, A., Saxena, S., Parveen, S., & Pandey, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00006-9
Emerging Alternative Therapies: Health-Promoting Microbes
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65455-8_1
Orenstein, R., Dubberke, E. R., Khanna, S., Lee, C., Yoho, D., Johnson, S., Hecht, G. A., Dupont, H. L., Gerding, D. N., Blount, K. F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19351485
Self-citationLangdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C.-A. D., Dubberke, E. R., & Dantas, G. (2021) · Figshare · doi:10.6084/m9.figshare.14052702
Self-citationLangdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C.-A. D., Dubberke, E. R., & Dantas, G. (2021) · Figshare · doi:10.6084/m9.figshare.14052684
Self-citationCristian, R.-E., Vrâncianu, C. O., Constantin, M., Păun, M., Milea, E. C., Malaescu, D., & Chifiriuc, M. C. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2722482
Novel options for the management of C. difficile : a look into the future
Granata, G., Petrosillo, N., & Taglietti, F. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2739273
Shareef, Z., Hussain, H. I., Aqib, A. I., Malik, M. S. U., & Rehman, S. U. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108871
Metadata
- Authors
- Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D. S., & Ramesh, M. S.
- Affiliations
- Mayo Clinic in Arizona (US)
- Washington University in St. Louis (US)
- Ochsner Medical Center (US)
- University of Chicago (US)
- Mayo Clinic (US)
- Henry Ford Health (US)
- Corresponding author
- Orenstein, Robert
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-12
- Volume
- 62
- Issue
- 5
- Pages
- 596-602
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2174455357
- Cited by
- 197
- References
- 30
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 34 · 2023: 24 · 2022: 19 · 2021: 15 · 2020: 16 · 2019: 17 · 2018: 17 · 2017: 14 · 2016: 20 · 2015: 1
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- recurrent Clostridium difficile infection, RBX2660, fecal microbiota transplantation, enema administration, drug safety, adverse events
- MeSH terms
- Fecal Microbiota Transplantation, Adult, Aged, Aged, 80 and over, Diarrhea, Enema, Enterocolitis, Pseudomembranous, Female, Humans, Male, Middle Aged, Prospective Studies, Recurrence, Clostridioides difficile, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.